Decision-making in ileocecal Crohn’s disease management: surgery versus pharmacotherapy

References

• Hanauer SB. Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities. Inflamm. Bowel Dis.12(Suppl. 1), S3–S9 (2006).
   PubMed Web of Science ®Google Scholar
• Rutgeerts PJ. An historical overview of the treatment of Crohn’s disease: why do we need biological therapies? Rev. Gastroenterol. Disord.4(Suppl. 3), S3–S9 (2004).
   PubMedGoogle Scholar
• Goldstein F. Immunosuppressant therapy of inflammatory bowel disease. Pharmacologic and clinical aspects. J. Clin. Gastroenterol.9, 654–658 (1987).
   PubMed Web of Science ®Google Scholar
• Andrews JM, Travis SP, Gibson PR, Gasche C. Systematic review: does concurrent therapy with 5-ASA and immunomodulators in inflammatory bowel disease improve outcomes? Aliment. Pharmacol. Ther.29, 459–469 (2009).
   PubMedGoogle Scholar
• Panaccione R, Rutgeerts P, Sandborn WJ, Feagan B, Schreiber S, Ghosh S. Review article: treatment algorithms to maximize remission and minimize corticosteroid dependence in patients with inflammatory bowel disease. Aliment. Pharmacol. Ther.28, 674–688 (2008).
   PubMed Web of Science ®Google Scholar
• Yun L, Hanauer S. Selecting appropriate anti-TNF agents in inflammatory bowel disease. Expert Rev. Gastroenterol. Hepatol.3, 235–248 (2009).
   PubMedGoogle Scholar
• Alos R, Hinojosa J. Timing of surgery in Crohn’s disease: a key issue in the management. World J. Gastroenterol.14, 5532–5539 (2008).
   PubMedGoogle Scholar
• Hyman NH. Crohn’s disease: drug therapy or surgery? Expert Rev. Gastroenterol. Hepatol.1, 187–192 (2007).
   PubMedGoogle Scholar
• Shariff U, Narula H, Speake W, Brown S. Terminal ileal Crohn’s disease: conservative surgeon and aggressive physician? Colorectal Dis.11, 522–523 (2009).
   PubMedGoogle Scholar
• Travis SP, Stange EF, Lemann M et al. European evidence based consensus on the diagnosis and management of Crohn’s disease: current management. Gut55(Suppl. 1), i16–i35 (2006).
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR, Abreu MT, Cohen R, Tremaine W. American Gastroenterological Association Institute medical position statement on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology130, 935–939 (2006).
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR, Hanauer SB, Sandborn WJ. Management of Crohn’s disease in adults. Am. J. Gastroenterol.104, 465–483 (2009).
   PubMed Web of Science ®Google Scholar
• Crohn BB, Ginzburg L, Oppenheimer GD. Regional ileitis. J. Am. Med. Assoc.1323–1329 (1932).
   Google Scholar
• Freeman HJ. Application of the Montreal classification for Crohn’s disease to a single clinician database of 1015 patients. Can. J. Gastroenterol.21, 363–366 (2007).
   PubMedGoogle Scholar
• Hyman NH, Fazio VW. Crohn’s disease of the small bowel. Compr. Ther.17, 38–42 (1991).
   PubMedGoogle Scholar
• D’Haens G, Baert F, van Assche G et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn’s disease: an open randomised trial. Lancet371, 660–667 (2008).
   PubMed Web of Science ®Google Scholar
• Herfarth H. Are we ready for top-down therapy for inflammatory bowel diseases: con. Expert. Rev. Gastroenterol. Hepatol.1, 249–255 (2007).
   PubMedGoogle Scholar
• van der Woude CJ, Hommes DW. Are we ready for top-down therapy for inflammatory bowel diseases: pro. Expert Rev. Gastroenterol. Hepatol.1, 243–248 (2007).
   PubMedGoogle Scholar
• Wong K, Bressler B. Mild to moderate Crohn’s disease: an evidence-based treatment algorithm. Drugs68, 2419–2425 (2008).
   PubMedGoogle Scholar
• Seow CH, Benchimol EI, Griffiths AM, Otley AR, Steinhart AH. Budesonide for induction of remission in Crohn’s disease. Cochrane Database Syst. Rev.16(3), CD000296 (2008).
   Google Scholar
• Prefontaine E, Sutherland LR, Macdonald JK, Cepoiu M. Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn’s disease. Cochrane Database Syst. Rev.21(1), CD000067 (2009).
   Google Scholar
• Candy S, Wright J, Gerber M, Adams G, Gerig M, Goodman R. A controlled double blind study of azathioprine in the management of Crohn’s disease. Gut37, 674–678 (1995).
   PubMed Web of Science ®Google Scholar
• Feagan BG, Fedorak RN, Irvine EJ et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn’s disease. North American Crohn’s Study Group Investigators. N. Engl. J. Med.342, 1627–1632 (2000).
   PubMed Web of Science ®Google Scholar
• Feagan BG, Rochon J, Fedorak RN et al. Methotrexate for the treatment of Crohn’s disease. The North American Crohn’s Study Group Investigators. N. Engl. J. Med.332, 292–297 (1995).
   PubMed Web of Science ®Google Scholar
• Targan SR, Hanauer SB, van Deventer SJ et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor a for Crohn’s disease. Crohn’s Disease cA2 Study Group. N. Engl. J. Med.337, 1029–1035 (1997).
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, D’Haens G, Targan S et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn’s disease. Gastroenterology117, 761–769 (1999).
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Feagan BG, Lichtenstein GR et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet359, 1541–1549 (2002).
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Sandborn WJ, Rutgeerts P et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trial. Gastroenterology130, 323–333 (2006).
   PubMed Web of Science ®Google Scholar
• Colombel JF, Sandborn WJ, Rutgeerts P et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology132, 52–65 (2007).
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Hanauer SB, Rutgeerts P et al. Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial. Gut56, 1232–1239 (2007).
   PubMed Web of Science ®Google Scholar
• Behm BW, Bickston SJ. Tumor necrosis factor-α antibody for maintenance of remission in Crohn's disease. Cochrane Database Syst. Rev.23(1), CD006893 (2008).
   Google Scholar
• Baert F, Noman M, Vermeire S et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s disease. N. Engl. J. Med.348, 601–608 (2003).
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Rutgeerts P, Enns R et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann. Intern. Med.146, 829–838 (2007).
   PubMed Web of Science ®Google Scholar
• Toruner M, Loftus EV Jr, Harmsen WS et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology134, 929–936 (2008).
   PubMed Web of Science ®Google Scholar
• Beaugerie L, Brousse N, Bouvier AM et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet374, 1617–1625 (2009).
   PubMed Web of Science ®Google Scholar
• Hanauer SB. Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: is the synergy worth the risk? Gut56, 1181–1183 (2007).
   PubMed Web of Science ®Google Scholar
• van Assche G, Vermeire S, Rutgeerts P. Immunosuppression in inflammatory bowel disease: traditional, biological or both? Curr. Opin. Gastroenterol.25, 323–328 (2009).
   PubMed Web of Science ®Google Scholar
• Deshpande AR, Abreu MT. Combination therapy with infliximab and immunomodulators: is the glass half empty? Gastroenterology134, 2161–2163 (2008).
   PubMed Web of Science ®Google Scholar
• Vermeire S, Noman M, van Assche G, Baert F, D’Haens G, Rutgeerts P. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn’s disease. Gut56, 1226–1231 (2007).
   PubMed Web of Science ®Google Scholar
• Colombel JF, Rutgeerts P, Reinisch W et al. SONIC: a randomized, double-blind, controlled trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn’s disease naive to immunomodulators and biologic therapy. J. Crohn Colitis3, S45–S46 (2009).
   PubMedGoogle Scholar
• Shale M, Kanfer E, Panaccione R, Ghosh S. Hepatosplenic T-cell lymphoma in inflammatory bowel disease. Gut57, 1639–1641 (2008).
   PubMed Web of Science ®Google Scholar
• van Assche G, Magdelaine-Beuzelin C, D’Haens G et al.Withdrawal of immunosuppression in Crohn’s disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology134, 1861–1868 (2008).
   PubMed Web of Science ®Google Scholar
• Louis E, Vernier-Massouille G, Grimaud JC et al. Infliximab discontinuation in Crohn’s disease patients in stable remission on combined therapy with immunosuppressors: a prospective ongoing patient cohort. Gastroenterology136, A-146 (2009).
   Google Scholar
• Bernklev T, Jahnsen J, Schulz T et al. Course of disease, drug treatment and health-related quality of life in patients with inflammatory bowel disease 5 years after initial diagnosis. Eur. J. Gastroenterol. Hepatol.17, 1037–1045 (2005).
   PubMed Web of Science ®Google Scholar
• Feagan BG, Yan S, Bala M, Bao W, Lichtenstein GR. The effects of infliximab maintenance therapy on health-related quality of life. Am. J. Gastroenterol.98, 2232–2238 (2003).
   PubMed Web of Science ®Google Scholar
• Loftus EV, Feagan BG, Colombel JF et al. Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn’s disease: patient-reported outcomes of the CHARM trial. Am. J. Gastroenterol.103, 3132–3141 (2008).
   PubMed Web of Science ®Google Scholar
• Casellas F, Rodrigo L, Nino P, Pantiga C, Riestra S, Malagelada JR. Sustained improvement of health-related quality of life in Crohn’s disease patients treated with infliximab and azathioprine for 4 years. Inflamm. Bowel. Dis.13, 1395–1400 (2007).
   PubMed Web of Science ®Google Scholar
• Bodger K, Kikuchi T, Hughes D. Cost–effectiveness of biological therapy for Crohn’s disease: Markov cohort analyses incorporating United Kingdom patient-level cost data. Aliment. Pharmacol. Ther.30(3), 265–274 (2009).
   PubMed Web of Science ®Google Scholar
• Maartense S, Dunker MS, Slors JF et al. Laparoscopic-assisted versus open ileocolic resection for Crohn’s disease: a randomized trial. Ann. Surg.243, 143–149 (2006).
   PubMed Web of Science ®Google Scholar
• Milsom JW, Hammerhofer KA, Bohm B, Marcello P, Elson P, Fazio VW. Prospective, randomized trial comparing laparoscopic vs. conventional surgery for refractory ileocolic Crohn’s disease. Dis. Colon Rectum44, 1–8 (2001).
   PubMed Web of Science ®Google Scholar
• Polle SW, Wind J, Ubbink DT, Hommes DW, Gouma DJ, Bemelman WA. Short-term outcomes after laparoscopic ileocolic resection for Crohn’s disease. A systematic review. Dig. Surg.23, 346–357 (2006).
   PubMedGoogle Scholar
• Lesperance K, Martin MJ, Lehmann R, Brounts L, Steele SR. National trends and outcomes for the surgical therapy of ileocolonic Crohn’s disease: a population-based analysis of laparoscopic vs. open approaches. J. Gastrointest. Surg.13, 1251–1259 (2009).
   PubMed Web of Science ®Google Scholar
• Subramanian V, Pollok RC, Kang JY, Kumar D. Systematic review of postoperative complications in patients with inflammatory bowel disease treated with immunomodulators. Br. J. Surg.93, 793–799 (2006).
   PubMedGoogle Scholar
• Appau KA, Fazio VW, Shen B et al. Use of infliximab within 3 months of ileocolonic resection is associated with adverse postoperative outcomes in Crohn’s patients. J. Gastrointest. Surg.12, 1738–1744 (2008).
   PubMed Web of Science ®Google Scholar
• Kunitake H, Hodin R, Shellito PC, Sands BE, Korzenik J, Bordeianou L. Perioperative treatment with infliximab in patients with Crohn’s disease and ulcerative colitis is not associated with an increased rate of postoperative complications. J. Gastrointest. Surg.12, 1730–1736 (2008).
   PubMed Web of Science ®Google Scholar
• Stocchi L, Milsom JW, Fazio VW. Long-term outcomes of laparoscopic versus open ileocolic resection for Crohn’s disease: follow-up of a prospective randomized trial. Surgery144, 622–627 (2008).
   PubMed Web of Science ®Google Scholar
• Eshuis EJ, Slors JF, Stokkers PC et al. Long-term results after laparoscopic-assisted versus open ileocolic resection for Crohn’s disease. Br. J. Surg97(4), 563–568 (2010).
   PubMed Web of Science ®Google Scholar
• Young-Fadok TM, HallLong K, McConnell EJ, Gomez Rey G, Cabanela RL. Advantages of laparoscopic resection for ileocolic Crohn’s disease. Improved outcomes and reduced costs. Surg. Endosc.15, 450–454 (2001).
   PubMed Web of Science ®Google Scholar
• Aratari A, Papi C, Leandro G, Viscido A, Capurso L, Caprilli R. Early versus late surgery for ileo-caecal Crohn’s disease. Aliment. Pharmacol. Ther.26, 1303–1312 (2007).
   PubMed Web of Science ®Google Scholar
• Tekkis PP, Nicholls RJ. Early or late surgery for patients with ileocecal Crohn’s disease? Nat. Clin. Pract. Gastroenterol. Hepatol.5, 304–305 (2008).
   PubMedGoogle Scholar
• Scott NA, Hughes LE. Timing of ileocolonic resection for symptomatic Crohn’s disease – the patient’s view. Gut35, 656–657 (1994).
   PubMedGoogle Scholar
• Eshuis EJ, Bemelman WA, van Bodegraven AA et al. Laparoscopic ileocolic resection versus infliximab treatment of distal ileitis in Crohn’s disease: a randomized multicenter trial (LIR!C-trial). BMC Surg.8, 15 (2008).
   PubMedGoogle Scholar
• Weersma RK, Stokkers PC, Cleynen I et al. Confirmation of multiple Crohn’s disease susceptibility loci in a large Dutch–Belgian cohort. Am. J. Gastroenterol.104, 630–638 (2009).
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Vermeire S, van Assche G. Biological therapies for inflammatory bowel diseases. Gastroenterology136, 1182–1197 (2009).
   PubMed Web of Science ®Google Scholar